Clinical Trials
-
Principal Investigator:
S. Zev Williams, MD, PhDResearchers at Columbia are looking at new treatments to help delay the start of menopause. This is a randomized trial where some women will receive medication and some will receive a placebo. The study will last approximately 12 weeks, followed by monthly follow-ups for 6 months. Participants will be compensated $1300 for compensation. -
Principal Investigator:
June Y. Hou, MDThe main purpose of this study is to: Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or in combination with cemiplimab to research subjects with ovarian cancer without too many side effects. The study will also look at the levels of REGN4018 and/or cemiplimab in the body and measure how well your body can remove the study drug(s). This is called pharmacokinetics. The study will also look at any signs that REGN4018 alone or with cemiplimab can treat cancer. -
Principal Investigator:
June Y. Hou, MDThe purpose of this research study is to test the safety and determine the highest tolerable dose of SL-172154 (study drug) that can be given with Pegylated Liposomal Doxorubicin (PLD) or Mirvetuximab Soravtansine (MIRV). Another purpose of this study is to understand if SL-127154 and PLD or MIRV is effective in managing ovarian cancer. The study drug, SL-172154 is an immunotherapy drug. Immunotherapies are treatments that use your bodys own immune (defense) system to help fight cancer. SL-172154 binds to a protein called CD47 on cancer cells and to a protein called CD40 on immune cells... -
Principal Investigator:
June Y. Hou, MDThe purpose of this research is to learn about what effects, both good and/or bad, an experimental drug called TransCon IL-2 / has when given by itself SOC chemotherapy, or experimental drug called TransCon TLR7/8 Agonist, or in combination with SOC chemotherapy. TransCon IL-2 / works by blocking the reproduction and spread of cancer cells. The study drugs TransCon IL-2 / and TransCon TLR7/8 Agonist (TLR7/8) have not been approved by the Food and Drug Administration FDA for your type of cancer. We also want to find a dose of TransCon IL-2 / that is safe and tolerable for adult patients who... -
Principal Investigator:
Jason D. Wright, MDXMT-1536 (upifitamab rilsodotin) is a targeted therapy, which means that it is directed specifically at a tumor. It is a type of antibody-drug conjugate; this means it has 2 parts that are joined together into one drug. The first part is an antibody that binds to NaPi2b (sodium-dependent phosphate transporter), a protein on the surface of the cells of your tumor. The second part is a cancer medicine that is attached to the antibody. When the antibody binds to NaPi2b, it carries the cancer medicine directly into the tumor cells to kill them. XMT-1536 is the study drug and a placebo is an... -
Principal Investigator:
June Y. Hou, MDThe purpose of this study is to assess whether an investigational drug, called XmAb20717, has any effects on your cancer, and to determine if it is safe and well tolerated. XmAb20717 is a type of drug that can attach to 2 different proteins, call a bispecific antibody. These antibodies are designed to attach to a T-cell, a type of immune system cell, in your body and ultimately help the body to fight the cancer. An antibody is a special kind of protein that your body normally makes to fight infections and other types of harmful cells and substances in your body. Scientists can now produce... -
Principal Investigator:
June Y. Hou, MDParticipants are being invited to take part in a clinical research study because they have been diagnosed with locally advanced or metastatic solid tumors with mutations in the following genes: MRE11, RAD50, NBN, or CCNE1 amplification. If the participant takes part in the study, they will take an investigational drug referred to as ZN-c3 (Study Drug). Investigational means that the Study Drug is currently being tested and has not been approved by the U.S. Food and Drug Administration (FDA) or any other health or regulatory authority in other countries. The purpose of this study includes the... -
Principal Investigator:
Carolyn L. Westhoff, MDThe study is looking to evaluate levonogestrel butanoate as a possible new long-acting injectable for birth control. Levonogestrel butanoate is a type of hormone called progestin that has a long history of clinical use in a variety of birth control methods (e.g. pills, intrauterine devices, implants) and its efficacy and safety are well recognized. This study is seeking for healthy female volunteers between the ages of 18-40 years of age. Participation time is estimated to last up to 9 months with approximately 36 study visits. The first visit will last about 1 hour and all other visits will...